PhRMA Priorities Include Insurance Advocacy And Public Education On Patent Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
The association’s incoming chair, Bristol CEO Peter Dolan, is launching a five-year planning process.
You may also be interested in...
Sharer Replaces Dolan As PhRMA Chairman
Amgen CEO gets early promotion.
Sharer Replaces Dolan As PhRMA Chairman
Amgen CEO gets early promotion.
PhRMA’s Unlucky Class Of ‘06
Dolan's removal from Bristol creates succession challenge for the trade association as well.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: